|Bid||17.82 x 1900|
|Ask||17.83 x 3100|
|Day's Range||17.77 - 18.39|
|52 Week Range||10.85 - 33.82|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.29|
The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it. Express Scripts told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. It is also seeking a refund if the drugs don't work within a defined timeframe.The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.
The largest U.S. manager of prescription benefits is telling drugmakers that the current pricing model is broken, and taking aim at Amgen Inc and other makers of new migraine medicines to try and fix it. Express Scripts told Reuters it is pressing them to forego the usual strategy of setting a high U.S. list price, then lowering the cost for health plans through hefty rebates. The shift could help Express Scripts and other pharmacy benefits managers (PBMs) bring prices down, and deflect growing criticism of their role as "middlemen" in the drug supply chain.
Mylan NV (NASDAQ:MYL), while still trending upward on the stock market, is on pause and without direction at the moment. Markets do not yet recognize the growth potential in MYL stock. It produces the global supply of EpiPens for Mylan, but has manufacturing problems at its Missouri plant.
Eli Lilly & Co. (LLY) surpassed Wall Street analysts’ estimates for earnings per share (or EPS) and revenues during 4Q17. The company reported EPS of $1.14 on revenues of ~$6.2 billion, compared to the estimated EPS of $1.07 on revenues of ~$5.9 billion. Analysts expect the company to report EPS of $1.14 on revenues of $5.5 billion during 1Q18.
Teva Pharmaceutical Industries Ltd. announced today that it will release its first quarter 2018 financial results on Thursday, May 3, 2018 at 7:00 a.m. ET.
The joint venture called PGY Healthcare sells OTC product in more than 50 countries outside North America. The company will terminate operations on July 1.
Jazz Pharmaceuticals (JAZZ) estimates that in fiscal 2018, its net revenue will be $1.86 billion–$1.93 billion. Its estimated GAAP (generally accepted accounting principles) gross margin is 93% for 2018.
“We delivered modest top- and bottom-line growth in a challenging macro environment in the third quarter,” CEO David Taylor said.
Teva Pharmaceutical Industries [NYSE and TASE: TEVA] has announced that Teva and the Procter & Gamble Company [NYSE: PG] have agreed to terminate the PGT Healthcare partnership that the two companies established in 2011 to market OTC (Over The Counter) medicines. No significant (material) net financial transfer between Teva and P&G will result from the dissolution. PGT Healthcare has grown into a significant presence in over 50 countries, mainly in Europe and Asia, using market-leading brands such as Vick’s and ratiopharm.
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $312.5 million compared to $291 million in 4Q16. In fiscal 2017, Xyrem reported revenues of $1.2 billion compared to $1.1 billion in 2016, which reflected a 7% growth on a YoY basis. Xyrem is used for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy.
In 4Q17, Jazz Pharmaceuticals (JAZZ) generated revenues of $436.4 million compared to $396.6 in 4Q16, which reflected a 10% growth on a YoY (year-over-year) basis and a 6% growth quarter-over-quarter.
Sandoz, the generics arm of Novartis (NVS), includes pharmaceuticals and biotechnological active substances in its portfolio. Sandoz is expected to report growth in operating revenue in 1Q18.
Here’s a quick wrap up of other headlines making news today.
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves.